Navigation Links
Bavarian Nordic A/S - Half Year Interim Report 2009
Date:8/28/2009

the 2009 Genitourinary Cancers Symposium in Orlando, Florida.

The data, collected from three different studies confirm the excellent safety and efficacy results previously reported, and they support the further investigation in patients suffering from advanced prostate cancer. Also, the data indicate that PROSTVAC(TM) can be used in earlier disease settings and thus in a larger patient population.

In May 2009 detailed PROSTVAC(TM) data were presented at the 2009 ASCO Annual Meeting in Orlando, Florida. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study.

The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer, patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85).

The statistical significance in the final data set is (p=0.006). These data were improved compared to the headline data presented in the fall in connection with the first announcement.

PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and brief systemic symptoms of fatigue, fevers, and chills (10-30%) reported.

In July 2009, a review on PROSTVAC(TM) from key investigators from the National Cancer Institute (NCI) was published in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009. This is the most comprehensive and updated review on PROSTVAC(TM) so far.

Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, a
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies announced ... is joining its Board of Director as Chair of ... at Zillow Group, Chad oversees all finance, treasury and ... the company,s core finance, treasury and accounting functions, and ... nine acquisitions. In 2013, he was named Puget Sound ...
(Date:3/3/2015)... March 03, 2015 Crown Bioscience, Inc., ... has launched a new Life Science division specializing in ... research. , The first products released include in ... and soon to be released in vivo grade monoclonal ... to expand their life science portfolio with additional antibody ...
(Date:3/3/2015)... 2015 Fried, Frank, Harris, Shriver & Jacobson ... has joined the Firm as a partner in the ... New York office. Mr. Lewis concentrates on ... as other intellectual property and general litigation. A trained ... both plaintiffs and defendants in a range of technology-related ...
(Date:3/3/2015)... HubCast® Inc. ( http://www.hubcast.com ), the leader in ... its Global Print Supply Chain with next-day delivery of ... cities across 75 countries globally. The HubCast Global ... enterprises ease, speed, reach, quality, cost savings and control ... real-world delivery at postal address around the globe. ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4
... Osprey Pharmaceuticals U.S.A., a,privately-held company focused on ... leukocytes that are responsible,for initiating and maintaining ... raised $11 million in its first round ... by Burrill & Company with participation from,Novo ...
... NORTH BRUNSWICK, N.J. and NANJING, China, Sept. 3 ... strategic,alliance, combining the drug discovery expertise and project ... medicinal chemistry resources and,favorable cost structure of Acesys ... the alliance will encompass all,aspects of medicinal chemistry ...
... PPHM ) today announced that it will release,its ... 2009 on,September 9, 2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ... the,first quarter ended July 31, 2008 and will review ...
Cached Biology Technology:Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 2Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 3Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results 2
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... that it will expand urea deep placement (UDP)a technology that ... hectares (ha) of rice land, reaching about 1.6 million farm ... UDP is the insertion of large urea briquettes into the ... Farmers who use UDP can increase yields by 25% while ...
... of Vanderbilt researchers have demonstrated for the first time ... interference, can heal a genetic disorder in a live ... by the journal Endocrinology, shows that RNA interference can ... engineered to express a defective human hormone that interferes ...
... most successful invasive species in the world, having colonized parts ... South America. A new study sheds light on the secrets ... University of Illinois and the University of California at San ... Academy of Sciences. The Argentine ant is tiny, aggressive ...
Cached Biology News:Bangladesh to dramatically expand technology that doubles efficiency of urea fertilizer use 2RNA interference therapy heals growth deficiency disorder in a live animal 2RNA interference therapy heals growth deficiency disorder in a live animal 3RNA interference therapy heals growth deficiency disorder in a live animal 4Ant invaders eat the natives, then move down the food chain 2